Managers / Q4 2020 · view latest →
Corriente Advisors, LLC
CIK 0001406718 · 1401 FOCH ST, SUITE 100, FORT WORTH, TX, 76107 · 8178700400
Summary
Corriente Advisors, LLC reported $420M in U.S.-listed holdings across 19 positions for Q4 2020.
The portfolio is heavily concentrated: Maxar Technologies alone accounts for 23.0% of reported value.
Compared with Q3 2020, the fund opened 11 new positions and exited 8.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.1% · $387M
- Other · 5.8% · $24M
- ADR · 2.2% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CCJCAMECO CORP | NEW | +2.18M | 2.18M | +$29M | $29M |
| GPROGOPRO INC | NEW | +3.35M | 3.35M | +$28M | $28M |
| FIREEYE INC | NEW | +690.0K | 690.0K | +$16M | $16M |
| CMPSCOMPASS PATHWAYS PLC | NEW | +190.0K | 190.0K | +$9M | $9M |
| CURIS INC | NEW | +1.10M | 1.10M | +$9M | $9M |
| CONCERT PHARMACEUTICALS INC | NEW | +680.0K | 680.0K | +$9M | $9M |
| KTOSKRATOS DEFENSE & SEC SOLUTIO | NEW | +200.0K | 200.0K | +$5M | $5M |
| NXENEXGEN ENERGY LTD | NEW | +1.00M | 1.00M | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MAXAR TECHNOLOGIES INC | COM | 22.97% | $96M | 2.50M |
| 2 | REATA PHARMACEUTICALS INC | CL A | 15.45% | $65M | 525.0K |
| 3 | REPLREPLIMUNE GROUP INChistory → | COM | 11.22% | $47M | 1.24M |
| 4 | CRDFCARDIFF ONCOLOGY INChistory → | COM | 8.56% | $36M | 2.00M |
| 5 | CCJCAMECO CORPhistory → | COM | 6.94% | $29M | 2.18M |
| 6 | GPROGOPRO INChistory → | CL A | 6.60% | $28M | 3.35M |
| 7 | CUE BIOPHARMA INC | COM | 5.70% | $24M | 1.92M |
| 8 | TFF PHARMACEUTICALS INC | COM | 4.60% | $19M | 1.35M |
| 9 | FIREEYE INC | COM | 3.79% | $16M | 690.0K |
| 10 | APTOSE BIOSCIENCES INC | COM NEW | 3.02% | $13M | 2.90M |
| 11 | CMPSCOMPASS PATHWAYS PLChistory → | SPONSORED ADS | 2.15% | $9M | 190.0K |
| 12 | CURIS INC | COM NEW | 2.14% | $9M | 1.10M |
| 13 | CONCERT PHARMACEUTICALS INC | COM | 2.05% | $9M | 680.0K |
| 14 | DMACDIAMEDICA THERAPEUTICS INChistory → | COM NEW | 1.95% | $8M | 806.9K |
| 15 | KTOSKRATOS DEFENSE & SEC SOLUTIOhistory → | COM NEW | 1.31% | $5M | 200.0K |
| 16 | NXENEXGEN ENERGY LTD | COM | 0.66% | $3M | 1.00M |
| 17 | ONCORUS INC | COM | 0.60% | $3M | 78.0K |
| 18 | OCULOCULAR THERAPEUTIX INC | COM | 0.27% | $1M | 53.9K |
| 19 | QSQUANTUMSCAPE CORP | COM CL A | 0.02% | $84,000 | 1.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $10M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 7 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $10,872 | 2 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $976,400 | 2 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $0 | 1 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $90M | 5 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $237M | 5 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $268M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $12M | 3 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $52M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $185M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $272M | 10 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $420M | 19 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 16 | Nov 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $154M | 16 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 11 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $186M | 17 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.